Figure 1 | Scientific Reports

Figure 1

From: Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway

Figure 1

miR-3127-5p expression is down-regulated in NSCLC tumor tissues and low miR-3127-5p levels correlate with unfavorable prognosis in patients with NSCLC.

(A): miRNA expression in primary tumor tissues and tissues from relapse tumors were evaluated by microarray analysis. (N = 3, P: primary tumor; R: recurrent tumor, miRNAs with log2 R/P<-0.8 or log2R/P>0.8 were shown. miR-3127-5p, miR-3940-5p, miR-4294 and miR-4447 for validation were indicated). (B): The expression of miR-3127-5p was significantly down-regulated in relapsed tumor tissue compared to paired primary tumor tissue. Paired Student's t-test (N = 15). (C): The expression of miR-3127-5p in normal, tumor-adjacent and tumor tissues of 177 matched NSCLC samples. N: normal; TN: tumor adjacent normal; T: tumor. Data were analyzed using Wilcoxon Mann Whitney U test; middle line: median; upper and bottom line: min and max; upper and bottom edge of box: 25% and 75% IQR. (D): Reduced miR-3127-5p expression is associated with shorter overall survival in patients with NSCLC (Low: n = 59; Middle: n = 58; High: n = 58; log-rank test; 2YS: 2-year overall survival). (E): Left panel: miR-3127-5p expression was significantly down-regulated in Ki-67-positive NSCLC tumors (N = 177, Wilcoxon Mann Whitney U test). Right panel: Representative photographs of Ki-67 IHC positive and negative NSCLC tissues (ADC: adenocarcinoma; SQC: squamous carcinoma; AD-SQC: adeno-squamous carcinoma; Numbers in parentheses: -ΔΔCT for miR-3127-5p).

Back to article page